Підписатись
Ярослав Шпарик
Ярослав Шпарик
Lviv cancer center
Немає підтвердженої електронної адреси
Назва
Посилання
Посилання
Рік
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
20992015
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
MER O'Brien, TE Ciuleanu, H Tsekov, Y Shparyk, B Cuceviá, G Juhasz, ...
Journal of Clinical Oncology 24 (34), 5441-5447, 2006
7212006
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ...
The Lancet 388 (10063), 2997-3005, 2016
6042016
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal …
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
5782016
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
V Diéras, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ...
The lancet oncology 21 (10), 1269-1282, 2020
2662020
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ …
JR Hecht, YJ Bang, S Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 31 (15_suppl), LBA4001-LBA4001, 2013
2112013
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized …
HS Han, V Diéras, M Robson, M Palácová, PK Marcom, A Jager, ...
Annals of Oncology 29 (1), 154-161, 2018
1762018
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, ...
J Clin Oncol 31 (10), 1341-1347, 2013
1502013
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
HS Rugo, V Diéras, KA Gelmon, RS Finn, DJ Slamon, M Martin, P Neven, ...
Annals of Oncology 29 (4), 888-894, 2018
1482018
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN …
BJ Monk, N Colombo, AM Oza, K Fujiwara, MJ Birrer, L Randall, ...
The lancet oncology 22 (9), 1275-1289, 2021
1382021
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled …
D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, ...
European journal of cancer 70, 146-155, 2017
1332017
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced …
RS Finn, K Boer, I Bondarenko, R Patel, T Pinter, M Schmidt, YV Shparyk, ...
Breast cancer research and treatment 183 (2), 419-428, 2020
1132020
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open …
A Romera, S Peredpaya, Y Shparyk, I Bondarenko, GM Bariani, ...
The Lancet Gastroenterology & Hepatology 3 (12), 845-855, 2018
1082018
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...
Annals of Oncology 30 (5), 766-773, 2019
1072019
Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with …
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, JH Ahn, ...
Journal of Clinical Oncology 36 (10), 968-974, 2018
952018
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label …
R Kristeleit, A Lisyanskaya, A Fedenko, M Dvorkin, AC de Melo, ...
The Lancet Oncology 23 (4), 465-478, 2022
912022
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced …
RS Finn, J Crown, I Lang, K Boer, I Bondarenko, SO Kulyk, J Ettl, R Patel, ...
Journal of Clinical Oncology 35 (15_suppl), 1001-1001, 2017
812017
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer
NK Ibrahim, KO Yariz, I Bondarenko, A Manikhas, V Semiglazov, ...
Clinical Cancer Research 17 (21), 6822-6830, 2011
712011
Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
Cancer Research 74 (19), 2014
702014
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant …
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, JH Ahn, SA Im, ...
European Journal of Cancer 93, 19-27, 2018
692018
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20